Timothy Sipos, MD
Ophthalmology · Houston, TXNPI 1487182473
Payments from drug & device makers
Across 70 payments — averaging $73.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$2K
- Alcon$971
- Astellas Pharma US Inc$402
- Carl Zeiss Meditec USA, Inc.$273
- AbbVie$254
- Genentech USA, Inc.$210
- plus $1K from 17 others
What the payments were for
- Consulting fees$1,20023%
- Food & beverage$3,96677%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 6 | $1,669 |
| Alcon | 9 | $971 |
| Astellas Pharma US Inc | 7 | $402 |
| Carl Zeiss Meditec USA, Inc. | 4 | $273 |
| AbbVie | 12 | $254 |
| Genentech USA, Inc. | 7 | $210 |
| Alimera Sciences, Inc. | 2 | $162 |
| Portola Pharmaceuticals, LLC | 2 | $158 |
| AstraZeneca(2 entities) | 2 | $144 |
| Regeneron Healthcare Solutions, Inc. | 4 | $126 |
| Mallinckrodt Hospital Products Inc. | 1 | $126 |
| Dutch Ophthalmic, USA | 2 | $125 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $118 |
| Glaukos Corporation | 1 | $111 |
| Apellis Pharmaceuticals, Inc. | 1 | $92 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $50 |
| Melinta Therapeutics, LLC | 2 | $47 |
| Pfizer | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Harrow Eye, LLC | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYP-1901$1,200
- Constellation$564
- YUTIQ$235
- AcrySof IQ PanOptix$132
- ACTHAR$126
- Izervay$125
- BEVYXXA$125
- CRESEMBA$125
- STELLARIS$118
- enVista MX60 IOL$118
- VABYSMO$115
- iStent inject W$111
- AcrySof$108
How this compares
$5,166 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 264 | $7,455 |
| MoxifloxacinMoxifloxacin Hcl | 148 | $3,100 |
| Difluprednate | 13 | $1,078 |
| Ketorolac Tromethamine | 45 | $790 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $221 |
| Brimonidine Tartrate | 19 | $90 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Houston
- David BrownHouston$51.7M
- John MichelettiHouston$3.3M
- Michael CaplanHouston$1.4M
- Shaheen KavoussiHouston$1.3M
- Kevin JongHouston$1.2M
- Stephen SladeHouston$1.2M
- Rosa TangHouston$1.1M
- Zaina Al-MohtasebHouston$1.1M
- Fiaz ZamanHouston$1M
- Stephen PflugfelderHouston$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.